ClinicalTrials.gg
CompletedNCT04391855Updated Sep 30, 2026

Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery

A Phase 4 interventional study of Tramadol with ropivacaine and Dexmedetomidine with ropivacaine in Analgesia, Pain, Postoperative and Spinal Stenosis, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment

How we know

Updated Sep 30, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing tramadol in Pain, Postoperative — 2 open to participants now, 5 under way, none of them phase 3. Tramadol · Pain, Postoperative.

Enrollment
20th of 34
72 · median 93
Started
2022
with 2 others
Phase 4
16 of 34
2 open now
Registered
18th of 34
by date
Lead sponsor
1 of 34
Aristotle University Of Thessaloniki

Among the 34 studies testing tramadol in Pain, Postoperative, this one is the 20th largest by enrollment, is one of 3 that started in 2022, is one of 16 in phase 4, and was the 18th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 34 studies testing tramadol in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tramadol in Pain, Postoperative, or all of them as a file.
02

Study summary

The rationale for multimodal analgesia is to achieve additive or synergistic analgesic properties while decreasing the incidence of side effects by reducing the dose of each agent. Nociceptive stimuli are known to activate the release of the excitatory amino acid glutamate in the dorsal horn of the spinal cord. The resultant activation of NMDA receptors causes calcium entry into the cell and triggers central sensitization. This mechanism is involved in the perception of pain and mainly accounts for its persistence during the postoperative period.

Peri-incisional injection of local anesthetics is an effective method for pain relief after many surgical procedures, as it can reduce postoperative analgesic consumption. Ropivacaine is a propyl analog of bupivacaine with a longer duration of action with a much safer cardiotoxicity profile than bupivacaine. Thus, a combination of local anesthetic with other analgesic factors, such as opioids, dexmedetomidine, clonidine, ketamine, magnesium sulfate, dexamethasone is suggested for a better analgesic outcome.

Dexmedetomidine, a highly selective a2-adrenergic receptor agonist, has been the focus of interest for its broad spectrum (sedative, analgesic, and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications. The intravenous, intramuscular, intrathecal, epidural, and perineural use of this agent enhances analgesic effects.

Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak m receptor agonist) and nonopioid receptors (inhibits the reuptake of noradrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway. It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.

It was reported that NMDA antagonists could prolong the analgesic effect of bupivacaine to even a week, as well as inhibit hyperalgesia. Magnesium sulfate (MGS) is a non-competitive antagonist of N-methyl, D-aspartate (NMDA) receptors with an analgesic effect and is essential for the release of acetylcholine from the presynaptic terminals and, similar to calcium channel blockers (CCB), can prevent the entry of calcium into the cell.

Aim of the study is to evaluate and compare the postoperative analgesic efficacy of tramadol, dexmedetomidine, and magnesium when added to ropivacaine as an adjuvant for wound infiltration following spine surgery.

Read the detailed description

Each participant will receive standard monitoring (ECG, SpO2, capnography, SBP, oesophageal temperature) and intravenous access will be established. A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and remifentanil in TCI (target-controlled infusion). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anesthesia will be maintained with desflurane in a 50% air/O2 mixture A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and remifentanil in TCI (target-controlled infusion). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anesthesia will be maintained with air to oxygen mixture of 50%, and desflurane adjusted to achieve a target BIS between 40 and 50. Remifentanil target level will be titrated according to analgesic demands defined by a > 20% change of heart rate or blood pressure compared with baseline. The duration of both anesthesia and surgical procedure will be registered. Furthermore, the level of sedation upon anesthesia emergence will be recorded using the Ramsey sedation scale.

Postoperatively pain assessment will be performed by the Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS) at anesthesia emergence and at 2, 4, 6, 12, 18, and 24 h after surgery conclusion. Time to first analgesic request and total analgesics consumption postoperatively (morphine equivalents) will be recorded.

Episodes of shivering, as well as episodes of nausea and vomiting (PONV) and other postoperative adverse events, will be recorded at emergence and 24 hours thereafter.

Finally, patients' global satisfaction will be assessed the second day and one month after surgery using the Quality of Recovery Scale(QoR-40). In the meantime, blood samples will be taken at the time before the surgical stimulus, 6 hours and 24 hours after wound infiltration to measure cortisol, TNF-a, and IL-6 plasma concentration.

03

Conditions studied

  • Analgesia
  • Pain, Postoperative
  • Spinal Stenosis
  • Spinal Disease

Keywords

  • analgesia
  • pain score
  • tramadol
  • dexmedetomidine
  • magnesium
  • opioid consumption
  • spine surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged between 18 and 80 years
  • ASA Physical status 1 to 3
  • Elective or semi-elective one-level lumbar laminectomy or discectomy surgery
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Chronic use of opioids
  • Drugs or alcohol abuse
  • Neurological disorders
  • Local anesthetics toxicity
  • Myopathy
  • Cardiac conductance disturbances
  • Hepatic failure
  • Renal failure
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Tramadol with ropivacaine

    Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration

    Drug: Tramadol with ropivacaine

  • Experimental
    Dexmedetomidine with ropivacaine

    Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration

    Drug: Dexmedetomidine with ropivacaine

  • Experimental
    Magnesium with ropivacaine

    Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration

    Drug: Magnesium with ropivacaine

  • Placebo comparator
    Placebo with ropivacaine

    Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration

    Drug: Ropivacaine plus normal saline

Interventions

  • DrugTramadol with ropivacaine

    Drug pages: TramadolStudies of TramadolTramadol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

    Also known as: TR

  • DrugDexmedetomidine with ropivacaine

    Drug pages: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

    Also known as: DR

  • DrugMagnesium with ropivacaine

    Drug pages: MagnesiumStudies of MagnesiumMagnesium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

    Also known as: MR

  • DrugRopivacaine plus normal saline

    A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.

    Also known as: R

06

What researchers measure

Primary outcomes

  1. Analgesics consumption postoperatively in morphine equivalents

    The difference in analgesic consumption (assessed as mg of morphine equivalents) postoperatively after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9%

    Time frame: 24 hours after the emergence from anesthesia

Secondary outcomes

  1. Time to first analgesic request in minutes

    The difference in the time frame (minutes) for analgesia request after emergence from anesthesia after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9%

    Time frame: 24 hours after the emergence from anesthesia

  2. Pain intensity postoperatively

    The difference in pain intensity postoperatively assessed by Visual Analogue Scale (graded from 0 defining absence of pain to 10 meaning extreme pain) or Numerical Pain Scale (graded from 0 defining no pain to 10 the worst pain ever experienced) after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9%

    Time frame: At 10 minutes after emergence from anesthesia, and 2, 4, 6, 12, 18 and 24 hours after the emergence from anesthesia

  3. Plasma concentration of TNF-a and IL-6

    Levels of TNF-a and IL-6 in pg/ml will be measured from blood samples at the times before surgical stimulus, at 6 hours and 24 hours after wound infiltration, as stress-response biomarkers.

    Time frame: Before wound infiltration, and at 6 and 24 hours thereafter

  4. Plasma concentration of cortisol

    Levels of cortisol (in mcg/dL) will be measured from blood samples at the times before surgical stimulus, at 6 hours and 24 hours after wound infiltration, as stress-response biomarkers.

    Time frame: Before wound infiltration, and at 6 and 24 hours thereafter

Other outcomes

  1. Patients' sedation level after emergence

    The level of sedation will be assessed after emergence using the Ramsey sedation scale in each participant, which ranges between 1 (anxious and restless patient) to 6 (unresponsive patient).

    Time frame: At 5 minutes after emergence from anesthesia

  2. Postoperative adverse effects

    The incidence of shivering, pruritus, nausea /vomiting, or any other adverse effect postoperatively after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9%

    Time frame: 24 hours after the emergence from anesthesia

  3. Quality of Recovery

    The quality of recovery and overall satisfaction of each participant will be assessed using the Quality of Recovery Scale (QoR-40) ranging from 0 the worst to 200 the best value.

    Time frame: At 48 hours postoperatively and one month after hospital discharge

07

Study locations

1 site
  • AHEPA University Hospital
    Thessaloniki, 54636, Greece
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Nov 2024, 29 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 29 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start May 2020 → May 2022, primary completion Nov 2022 → Nov 2024 and completion Dec 2022 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 18, 2020
StartActual
May 10, 2022was May 2020
Primary completionActual
Nov 8, 2024was Nov 2022
CompletionActual
Dec 10, 2024was Dec 2022
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 10, 2020→May 10, 2022
Sep 30, 2026
Primary completion
Nov 8, 2022→Nov 8, 2024
Sep 30, 2026
Study completion
Dec 10, 2022→Dec 10, 2024
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Time to first analgesic request in minutesNow Analgesics consumption postoperatively in morphine equivalentsTime frame: 24 hours after the emergence from anesthesia
Sep 30, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Analgesics consumption postoperatively in morphine equivalentsNow Time to first analgesic request in minutesTime frame: 24 hours after the emergence from anesthesia
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date May 10, 2020→May 10, 2022
    Primary completion Nov 8, 2022→Nov 8, 2024
    Study completion Dec 10, 2022→Dec 10, 2024
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Time to first analgesic request in minutesNow Analgesics consumption postoperatively in morphine equivalentsTime frame: 24 hours after the emergence from anesthesia
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Analgesics consumption postoperatively in morphine equivalentsNow Time to first analgesic request in minutesTime frame: 24 hours after the emergence from anesthesia
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04391855
Responsible party
Georgia Tsaousi (Associate Professor, Aristotle University Of Thessaloniki) — Principal investigator
First posted
May 18, 2020
Start date
May 10, 2022
Primary completion
Nov 8, 2024
Completion
Dec 10, 2024
Last update
Sep 30, 2026

Study contacts

Georgia Tsaousi
principal investigator · Aristotle University Of Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Ropivacaine · Dexmedetomidine · Magnesium

Start the discussion